Skip to main content

AP-SA02

FDA Grants Breakthrough Therapy Status to Armata's AP-SA02 Phage Drug

FDA Grants Breakthrough Therapy Status to Armata's AP-SA02 Phage Drug

Los Angeles – September 17, 2026 -- The U.S. Food and Drug Administration has granted Breakthrough Therapy designation to Armata Pharmaceuticals' AP-SA02, an intravenous multi-phage candidate for complicated Staphylococcus aureus bacteremia, stacking the designation atop existing Fast Track and Qualified Infectious Disease Product status.